PLK1, A Potential Target for Cancer Therapy

Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive its progression. PLK1 overexpression has been found in a variety of human cancers and was associated with poor prognoses in cancers. Many studies have showed that inhibition of PLK1 could lead to death of cancer cells by interfering with multiple stages of mitosis. Thus, PLK1 is expected to be a potential target for cancer therapy. In this article, we examined PLK1’s structural characteristics, its regulatory roles in cell mitosis, PLK1 expression, and its association with survival prognoses of cancer patients in a wide variety of cancer types, PLK1 interaction networks, and PLK1 inhibitors under investigation. Finally, we discussed the key issues in the development of PLK1-targeted cancer therapy.

[1]  B. Schäfer,et al.  PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma. , 2015, Cancer research.

[2]  T. Rana,et al.  Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer , 2015, Oncotarget.

[3]  Mike Tyers,et al.  BioGRID: a general repository for interaction datasets , 2005, Nucleic Acids Res..

[4]  H. Lane,et al.  On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. , 1997, Biochemical and biophysical research communications.

[5]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[6]  Xin Xu,et al.  Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma , 2009, International journal of cancer.

[7]  Hongmin Wang,et al.  BRCA1 downregulates the kinase activity of Polo-like kinase 1 in response to replication stress , 2013, Cell cycle.

[8]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[9]  M. Lübbert,et al.  BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1). , 2010, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[10]  N. Takai,et al.  Polo-like kinase (PLK) expression in endometrial carcinoma. , 2001, Cancer letters.

[11]  R. Medema,et al.  Shared and separate functions of polo-like kinases and aurora kinases in cancer , 2010, Nature Reviews Cancer.

[12]  S. Dunn,et al.  Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells , 2012, Breast Cancer Research.

[13]  G. Adolf,et al.  BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity , 2009, Clinical Cancer Research.

[14]  N. Ahmad,et al.  Large-Scale Label-Free Comparative Proteomics Analysis of Polo-Like Kinase 1 Inhibition via the Small-Molecule Inhibitor BI 6727 (Volasertib) in BRAFV600E Mutant Melanoma Cells , 2014, Journal of proteome research.

[15]  Chien-Lin Liu,et al.  Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel. , 2016, International journal of oncology.

[16]  Kyle A. Emmitte,et al.  In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1 , 2007, Molecular Cancer Therapeutics.

[17]  M. Bissell,et al.  Polo-like kinase 1 is involved in invasion through extracellular matrix. , 2007, Cancer research.

[18]  Xiao-wei Zhu,et al.  Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma. , 2012, Acta histochemica.

[19]  A. Benz,et al.  Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. , 2012, Neoplasia.

[20]  Erich A Nigg,et al.  The crystal structure of the human polo‐like kinase‐1 polo box domain and its phospho‐peptide complex , 2003, The EMBO journal.

[21]  J. Ju,et al.  Downregulation of PLK1 by RNAi attenuates the tumorigenicity of esophageal squamous cell carcinoma cells via promoting apoptosis and inhibiting angiogenesis. , 2015, Neoplasma.

[22]  Fangzhou Song,et al.  Silencing of Polo-Like Kinase (Plk) 1 via siRNA Causes Inhibition of Growth and Induction of Apoptosis in Human Esophageal Cancer Cells , 2008, Oncology.

[23]  Christian Sillaber,et al.  Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. , 2010, Cancer research.

[24]  Zhe Zhang,et al.  Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells , 2013, Tumor Biology.

[25]  R. Grobholz,et al.  Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. , 2000, Pathology, research and practice.

[26]  E. Henske,et al.  Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner. , 2006, Human molecular genetics.

[27]  N. Ahmad,et al.  The role of polo-like kinase 1 in carcinogenesis: cause or consequence? , 2013, Cancer research.

[28]  S. Loening,et al.  Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades , 2004, The Prostate.

[29]  Patrick J. Paddison,et al.  A High-Content Small Molecule Screen Identifies Sensitivity of Glioblastoma Stem Cells to Inhibition of Polo-Like Kinase 1 , 2013, PloS one.

[30]  J. Qin,et al.  M Phase-specific Phosphorylation of BRCA2 by Polo-like Kinase 1 Correlates with the Dissociation of the BRCA2-P/CAF Complex* , 2003, Journal of Biological Chemistry.

[31]  T. Karn,et al.  Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Xiaoqi Liu,et al.  Molecular interactions of Polo-like-kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1 , 2004, Journal of Cell Science.

[33]  Y. Jang,et al.  Mitotic DNA damage response: Polo-like Kinase-1 is dephosphorylated through ATM-Chk1 pathway , 2010, Cell cycle.

[34]  Vincenzo Costanzo,et al.  Polo-like kinase 1 reaches beyond mitosis--cytokinesis, DNA damage response, and development. , 2008, Current opinion in cell biology.

[35]  Marc C Nicklaus,et al.  Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1. , 2010, ACS medicinal chemistry letters.

[36]  Xueda Hu,et al.  Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches. , 2016, Trends in genetics : TIG.

[37]  A. Miyauchi,et al.  Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma , 2004, British Journal of Cancer.

[38]  Michael D. Taylor,et al.  Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells , 2012, BMC Cancer.

[39]  I. A. Asteriti,et al.  Cross-Talk between AURKA and Plk1 in Mitotic Entry and Spindle Assembly , 2015, Front. Oncol..

[40]  Xia Li,et al.  Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis. , 2015, Oncology reports.

[41]  M. Tsao,et al.  Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. , 2004, Molecular cancer therapeutics.

[42]  W. Weichert,et al.  Polo-like kinase 1 expression is a prognostic factor in human colon cancer. , 2005, World journal of gastroenterology.

[43]  Stephen S. Taylor,et al.  Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery , 2008, Nature.

[44]  Jing Wang,et al.  Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[45]  A. Venkitaraman,et al.  Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression , 2004, Oncogene.

[46]  B. Kopnin.  Targets of oncogenes and tumor suppressors: key for understanding basic mechanisms of carcinogenesis. , 2000, Biochemistry. Biokhimiia.

[47]  A. Jimeno,et al.  Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies , 2014, Clinical Cancer Research.

[48]  X. Miao,et al.  Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. , 2009, World journal of gastroenterology.

[49]  Hongtao Yu,et al.  The Bub1–Plk1 kinase complex promotes spindle checkpoint signalling through Cdc20 phosphorylation , 2016, Nature Communications.

[50]  Takao Takahashi,et al.  Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers , 2003, Cancer science.

[51]  K. Strebhardt,et al.  PLK (polo‐like kinase), a new prognostic marker for oropharyngeal carcinomas , 2000, International journal of cancer.

[52]  N. Ahmad,et al.  Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics , 2016, Molecular Cancer Therapeutics.

[53]  Changjiang Jin,et al.  Phosphorylation of Tara by Plk1 is essential for faithful chromosome segregation in mitosis. , 2012, Experimental cell research.

[54]  S. Elledge,et al.  The tumor suppressor CYLD regulates entry into mitosis , 2007, Proceedings of the National Academy of Sciences.

[55]  N. Takai,et al.  Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. , 2001, Cancer letters.

[56]  C. Liu,et al.  The expression of Nek7, FoxM1, and Plk1 in gallbladder cancer and their relationships to clinicopathologic features and survival , 2013, Clinical and Translational Oncology.

[57]  A. Sharrocks,et al.  The FOXM1-PLK1 axis is commonly upregulated in oesophageal adenocarcinoma , 2012, British Journal of Cancer.

[58]  R. Medema,et al.  Polo-Like Kinases: A Team in Control of the Division , 2006, Cell cycle.

[59]  Paul Taylor,et al.  Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance , 2006, Nature chemical biology.

[60]  F. Fuller-Pace,et al.  p53-dependent repression of polo-like kinase-1 (PLK1) , 2010, Cell cycle.

[61]  K. Feenstra,et al.  Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets. , 2011, Cancer research.

[62]  A. Sharrocks,et al.  FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas , 2015, BMC Research Notes.

[63]  J. Jackson,et al.  Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. , 2009, Bioorganic & medicinal chemistry letters.

[64]  R. Matkowski,et al.  Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up , 2016, Oncology letters.

[65]  M. Wiedmann,et al.  Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma. , 2011, Anticancer research.

[66]  H. Lane,et al.  The family of polo-like kinases. , 1996, Progress in cell cycle research.

[67]  Michael B Yaffe,et al.  Structure and function of Polo-like kinases , 2005, Oncogene.

[68]  A. Thompson,et al.  Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome , 2012, Breast Cancer Research.

[69]  C. Rödel,et al.  Tumorigenesis and Neoplastic Progression Polo-Like Kinase 1 as Predictive Marker and Therapeutic Target for Radiotherapy in Rectal Cancer , 2010 .

[70]  S. Keir,et al.  Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program , 2014, Pediatric blood & cancer.

[71]  Richard Simon,et al.  Identification of potential synthetic lethal genes to p53 using a computational biology approach , 2013, BMC Medical Genomics.

[72]  Kozo Tanaka,et al.  CLIP-170 recruits PLK1 to kinetochores during early mitosis for chromosome alignment , 2014, Journal of Cell Science.

[73]  V. Feher,et al.  Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1). , 2013, Bioorganic & medicinal chemistry letters.

[74]  P. C. de Witt Hamer,et al.  WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe , 2011, Clinical Cancer Research.

[75]  Kiranmai Gumireddy,et al.  ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. , 2005, Cancer cell.

[76]  K. Strebhardt,et al.  Tumorigenesis and Neoplastic Progression Polo-Box Domain Inhibitor Poloxin Activates the Spindle Assembly Checkpoint and Inhibits Tumor Growth in Vivo , 2011 .

[77]  K. Akazawa,et al.  Prognostic significance of polo-like kinase expression in esophageal carcinoma. , 1999, International journal of oncology.

[78]  P. Taylor,et al.  Ligand discovery and virtual screening using the program LIDAEUS , 2008, British journal of pharmacology.

[79]  B. Kuster,et al.  Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells. , 2015, ACS chemical biology.

[80]  Hongtao Yu,et al.  Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is required for the kinetochore localization of Plk1. , 2006, Molecular biology of the cell.

[81]  Guojun Zhang,et al.  High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. , 2013, Urologic oncology.

[82]  Hao Li,et al.  Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression , 2008, Nature Cell Biology.

[83]  Guojun Zhang,et al.  FOXM1 participates in PLK1-regulated cell cycle progression in renal cell cancer cells. , 2016, Oncology letters.

[84]  M. Hengstschläger,et al.  The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. , 2008, Mutation research.

[85]  T. Kawamoto,et al.  TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens , 2011, Molecular Cancer Therapeutics.

[86]  W. Weichert,et al.  Overexpression of Polo-Like Kinase 1 Is a Common and Early Event in Pancreatic Cancer , 2005, Pancreatology.

[87]  A. Jimeno,et al.  A Fine-Needle Aspirate–Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.

[88]  Sang‐Gun Ahn,et al.  The antitumor effect of PLK1 and HSF1 double knockdown on human oral carcinoma cells. , 2010, International journal of oncology.

[89]  Hongzhuan Yin,et al.  High Expression of Polo-Like Kinase 1 Is Associated with Early Development of Hepatocellular Carcinoma , 2014, International journal of genomics.

[90]  A. Ochocka,et al.  Polo‐like kinase‐1 phosphorylates MDM2 at Ser260 and stimulates MDM2‐mediated p53 turnover , 2009, FEBS Letters.

[91]  Y. Degenhardt,et al.  Targeting Polo-like Kinase in Cancer Therapy , 2010, Clinical Cancer Research.

[92]  E. Nigg,et al.  Tension-sensitive Plk1 phosphorylation on BubR1 regulates the stability of kinetochore microtubule interactions. , 2007, Genes & development.

[93]  Y. Canitrot,et al.  Polo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaks , 2016, Oncotarget.

[94]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[95]  D. Benoit,et al.  pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. , 2010, Molecular pharmaceutics.

[96]  E. Nigg,et al.  Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. , 2007, Molecular biology of the cell.

[97]  M. Kwon,et al.  The chromatin remodeller RSF1 is essential for PLK1 deposition and function at mitotic kinetochores , 2015, Nature Communications.

[98]  W. Weichert,et al.  Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma , 2004, British Journal of Cancer.

[99]  Yi Chen,et al.  Identification of novel, potent and selective inhibitors of Polo-like kinase 1. , 2012, Bioorganic & Medicinal Chemistry Letters.

[100]  J. Zuber,et al.  Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[101]  R. Paules,et al.  ATR Enforces the Topoisomerase II-dependent G2 Checkpoint through Inhibition of Plk1 Kinase* , 2002, The Journal of Biological Chemistry.

[102]  P. Schöffski.  Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. , 2009, The oncologist.

[103]  Wenfang Xu,et al.  Developments of polo-like kinase 1 (Plk1) inhibitors as anti-cancer agents. , 2013, Mini reviews in medicinal chemistry.

[104]  E. Sakamoto-Hojo,et al.  In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. , 2012, Journal of drugs in dermatology : JDD.

[105]  Min Liu,et al.  Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells , 2012, Cancer biology & therapy.

[106]  G. Schneider,et al.  Identification and Validation of a Potent Type II Inhibitor of Inactive Polo‐like Kinase 1 , 2009, ChemMedChem.

[107]  M. Figueroa,et al.  Epigenetic roles of MLL oncoproteins are dependent on NF-κB. , 2013, Cancer cell.

[108]  Jean-Pierre Gillet,et al.  Mechanisms of multidrug resistance in cancer. , 2010, Methods in molecular biology.

[109]  Y. Shukla,et al.  Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells. , 2010, Biochemical pharmacology.

[110]  H. Ackermann,et al.  Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer , 1997, Oncogene.

[111]  C. S. Lee,et al.  Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer , 2015, PloS one.

[112]  C. Linhart,et al.  Prognostic value of pololike kinase expression in melanomas. , 2000, JAMA.

[113]  P. Ramani,et al.  High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas , 2015, Journal of Neuro-Oncology.

[114]  P. Pauwels,et al.  Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor , 2016, Medicinal research reviews.

[115]  Nihal Ahmad,et al.  Silencing of polo‐like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[116]  W. Weichert,et al.  Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications , 2005, Virchows Archiv.

[117]  R. Khosravi‐Far,et al.  PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor. , 2014, Discoveries.

[118]  H. Saya,et al.  BubR1 localizes to centrosomes and suppresses centrosome amplification via regulating Plk1 activity in interphase cells , 2009, Oncogene.

[119]  C. Mawrin,et al.  Increased Human Polo-Like Kinase-1 Expression in Gliomas , 2001, Journal of Neuro-Oncology.

[120]  C. von Ilberg,et al.  Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. , 1999, Cancer research.

[121]  M. Malumbres,et al.  Functional evolution of Polo-like kinases , 2011 .

[122]  R. Kaufmann,et al.  Expression of polo‐like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease , 2002, Journal of cutaneous pathology.

[123]  K. Strebhardt,et al.  Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. , 2008, Chemistry & biology.

[124]  D. Stern,et al.  Polo-like Kinase 1 and Chk2 Interact and Co-localize to Centrosomes and the Midbody* , 2003, The Journal of Biological Chemistry.

[125]  Yun‐Sil Lee,et al.  HSF1 as a mitotic regulator: phosphorylation of HSF1 by Plk1 is essential for mitotic progression. , 2008, Cancer research.

[126]  I. Sumara,et al.  Molecular dynamics of PLK1 during mitosis , 2014, Molecular & cellular oncology.

[127]  Jürgen Bereiter-Hahn,et al.  Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. , 2002, Journal of the National Cancer Institute.

[128]  W. Mok,et al.  Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma. , 2012, World journal of gastroenterology.

[129]  Thomas Efferth,et al.  Polo-like kinase 1 as target for cancer therapy , 2012, Experimental Hematology & Oncology.

[130]  M. Buschbeck.  Strategies to Overcome Resistance to Targeted Protein Kinase Inhibitors in the Treatment of Cancer , 2006, Drugs in R&D.

[131]  W. Weichert,et al.  Expression patterns of polo‐like kinase 1 in human gastric cancer , 2006, Cancer science.

[132]  Gong Yang,et al.  Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells. , 2015, Cancer letters.

[133]  R. Gilbert,et al.  Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. , 2010, International journal of radiation oncology, biology, physics.

[134]  Akira Nakagawara,et al.  Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation* , 2004, Journal of Biological Chemistry.

[135]  C. Shaw,et al.  The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. , 2014, Cell reports.

[136]  O. Gavet,et al.  Activation of cyclin B1–Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis , 2010, The Journal of cell biology.

[137]  H. Wakimoto,et al.  Polo‐Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice , 2012, Stem cells.

[138]  N. Hosten,et al.  Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer , 2016, Gut.